AstraZeneca PLC $AZN Shares Purchased by Brucke Financial Inc.

Brucke Financial Inc. boosted its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 33.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,476 shares of the company’s stock after purchasing an additional 2,869 shares during the period. Brucke Financial Inc.’s holdings in AstraZeneca were worth $946,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. AlphaCore Capital LLC raised its holdings in AstraZeneca by 77.3% during the 3rd quarter. AlphaCore Capital LLC now owns 14,230 shares of the company’s stock worth $1,092,000 after buying an additional 6,206 shares during the period. US Bancorp DE raised its holdings in shares of AstraZeneca by 6.6% during the third quarter. US Bancorp DE now owns 242,181 shares of the company’s stock valued at $18,581,000 after acquiring an additional 15,065 shares during the period. RWA Wealth Partners LLC raised its holdings in shares of AstraZeneca by 11.6% during the third quarter. RWA Wealth Partners LLC now owns 61,933 shares of the company’s stock valued at $4,751,000 after acquiring an additional 6,444 shares during the period. North Star Asset Management Inc. lifted its position in shares of AstraZeneca by 23.6% in the 3rd quarter. North Star Asset Management Inc. now owns 5,314 shares of the company’s stock valued at $408,000 after acquiring an additional 1,014 shares in the last quarter. Finally, TD Asset Management Inc boosted its stake in AstraZeneca by 20.0% in the 3rd quarter. TD Asset Management Inc now owns 1,089,612 shares of the company’s stock worth $83,595,000 after purchasing an additional 181,273 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the company. Deutsche Bank Aktiengesellschaft restated a “sell” rating on shares of AstraZeneca in a report on Friday, February 6th. TD Cowen reissued a “buy” rating on shares of AstraZeneca in a research note on Tuesday, December 9th. Guggenheim restated a “buy” rating on shares of AstraZeneca in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “buy (b)” rating on shares of AstraZeneca in a research note on Wednesday, January 21st. Finally, HSBC reissued a “buy” rating and issued a $108.00 price target on shares of AstraZeneca in a research report on Wednesday, December 10th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $95.75.

AstraZeneca Trading Down 0.2%

Shares of AZN stock opened at $206.22 on Thursday. AstraZeneca PLC has a 12 month low of $122.48 and a 12 month high of $212.71. The company has a market cap of $319.82 billion, a PE ratio of 68.51, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. The company has a quick ratio of 0.69, a current ratio of 0.88 and a debt-to-equity ratio of 0.54. The business’s 50 day moving average is $131.31 and its two-hundred day moving average is $100.36.

AstraZeneca Dividend Announcement

The company also recently announced a dividend, which will be paid on Monday, March 23rd. Shareholders of record on Friday, February 20th will be given a dividend of $1.595 per share. The ex-dividend date of this dividend is Friday, February 20th. This represents a yield of 156.0%. AstraZeneca’s payout ratio is currently 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.